Kane Biotech (TSE:KNE) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kane Biotech has announced that BioStem Technologies will acquire exclusive U.S. distribution rights for its revyve Antimicrobial Wound Gel from ProgenaCare Global, marking a strategic move to enhance BioStem’s wound care portfolio. This acquisition is expected to significantly boost the market presence of revyve products in the U.S., leveraging BioStem’s strong growth and commercial infrastructure in the sector.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
